News

In Q1 2025, Zepbound earned $2.31bn, Mounjaro $3.84bn, Ozempic ~$4.99bn, and Wegovy ~$2.65bn of revenues - nearly $14bn in total, putting them on course to easily top $60bn revenues combined in 2025.
Novo Nordisk A/S’ (NYSE:NVO) executives allegedly ignored internal warnings that the company was unprepared to launch its ...
They burst onto the scene four years ago and are taking over the pharmaceutical world. New GLP-1-based drugs like Ozempic, ...
Popular weight-loss drugs like Ozempic and Zepbound have revolutionized how we tackle obesity. But now, emerging reports ...
CVS says the decision to cover Wegovy and exclude Zepbound is "forcing the drug manufacturers to compete with one another" and will encourage both Eli Lilly and Novo Nordisk to lower prices for their ...
Some less expensive versions of popular weight loss drugs are no longer available to patients, after the Food & Drug ...
Joe Gebbia, a confidant of the technology billionaire and a Tesla director, is also a leader of the federal cost-cutting team ...
Three people share the hoops they've jumped through, financial strain they've endured and risks they've taken on in order to ...
Two growth stocks in the healthcare industry stand out in particular. Here is what you need to know about each one and why ...
This change is happening because there’s another covered medication that’s safe and effective for your condition and may cost ...
"Employers have absorbed the majority of cost increases over the past four years, and they likely cannot continue to do so," ...
Top executives ignored warnings that the company was not sufficiently prepared for the launch of its weight-loss drug Wegovy, ...